AI-generated · Based on company filings and platform data · Not investment advice
Amgen (AMGN) Q3 2026 Earnings Brief: Revenue $10.37B, +8.5% YoY
Released Nov 3, 2026 (ET)
Quarter: Q3 2026, period ended 2026-09-30; released 2026-11-03 (ET).
In one line: Amgen's revenue in the third quarter of 2026 was US$10.37 billion, with adjusted earnings per share of US$6.45, exceeding analysts' consensus expectations by 11.6%.
Key numbers
| Metric | This quarter | Note |
|---|---|---|
| Revenue | $10.37B | YoY +8.5% |
| Adj. EPS vs consensus | $6.45 vs $5.78 | Beat (+11.6%) |
| GAAP diluted EPS | $7.08 | Different basis from consensus |
| Net margin | 37.3% | Net income $3.86B |
| Next-quarter EPS consensus | $5.63 | 27 analysts; revenue consensus $10.47B |
Three things to know
1. Revenue increased by 8.5% year-on-year
Revenue for the quarter was US$10.37 billion, an increase of 8.5% from US$9.56 billion in the same period last year, reflecting the continued expansion of the core product line.
2. Net profit margin reached 37.3%
The net profit margin for the quarter was 37.3%, corresponding to net income of US$3.86 billion, indicating that the company's profitability remains stable.
3. Adjusted EPS beat expectations
Adjusted earnings per share were $6.45, which was 11.6% higher than analysts’ consensus estimate of $5.78.
Market reaction
Results were released on 2026-11-03 (ET). From the last pre-report close (2026-11-02, $465.45) to the close of the first session after the report (2026-11-04, $478.48), the stock moved +2.80%. The report-day close was $461.26; the next session closed +3.73% from it (for after-hours releases, this leg better reflects the reaction to the report).
What to watch next
- Pay attention to the fourth quarter financial report date of 2026 (February 2, 2027) and the consensus EPS average of $5.63 for the next quarter.
- Pay attention to management’s explanation of clinical trial progress and regulatory developments in subsequent communications.
- Observe whether capital expenditure and R&D investment in the first nine months are in line with the established plan.
- Next report date (platform calendar): 2027-02-02
Sources
- Financials: fundamentals-svc (EDGAR filings, analyst consensus)
- Prices: fundamentals-svc /v1/candles-ondemand
- MD&A source: 10-Q (filed 2026-11-04)
- Company press release (8-K): SEC EDGAR